Precigen Beats Q3 2026 Estimates as PAPZIMEOS Powers Profit
As seen on the 24/7 Wall St. homepage on November 4, 2026.
Precigen hit positive operating cash flow a quarter ahead of its own target, with PAPZIMEOS net product revenue of $72.96 million. Second straight profitable quarter after a year of losses, and the EMA review plus pediatric development are the next catalysts.
Continue ReadingShow less
Precigen posted its second consecutive profitable quarter in Q3 2026, with GAAP earnings per share of $0.08 beating expectations. Total revenue of $74.15 million also came in ahead of estimates, driven almost entirely by PAPZIMEOS, the company's adenoviral immunotherapy for recurrent respiratory papillomatosis.
PAPZIMEOS net product revenue rose 37% sequentially as payer coverage expanded to over 315 million U.S. lives, and launch-to-date net product revenue reached $151 million. Net income came in at $35.77 million, a reversal from the net loss attributable to common shareholders of $325.34 million in the year-ago period, though that prior-year figure included charges on warrant liabilities and a non-cash deemed dividend on preferred stock that no longer apply.
Operating cash flow turned positive at $11.9 million, one full quarter ahead of management's own year-end 2026 target. CEO Helen Sabzevari noted that strong commercial uptake drove both the sequential revenue growth and the early cash flow inflection, calling it progress toward what she described as PAPZIMEOS's blockbuster potential. Well over 500 patients have initiated treatment and more than 300 have completed it, with the therapy increasingly recognized as the first-line standard of care for adult RRP.
Sponsored
The European Medicines Agency has validated and is reviewing a marketing authorization application for PAPZIMEOS in adult RRP, an EU orphan drug designation is already in hand, and pediatric development is underway. The company is also running an open-label redosing study aimed at converting partial responders to complete responders, and new Phase 2 data for pipeline candidate PRGN-2009 is expected at a forthcoming R&D Day.
The competitive landscape grew more complicated this quarter, with a rival RRP therapy receiving FDA approval, introducing a dynamic that management will need to address as adoption scales. Revenue is heavily concentrated in a single commercial product, long-term debt stands at $94.3 million, and trade receivables rose sharply to $96.5 million, factors that investors will want to monitor as the company works to sustain its newly positive cash position.
Sources
Mentioned: PGEN